[1] JOHANSSON J, STENER-VICTORIN E. Polycystic ovary syndrome: Effect and mechanisms of acupuncture for ovulation induction[J]. Evidence-based Complementary and Alternative Medicine, 2013, 2013: 762615. [2] DUMESIC D A, OBERFIELD S E, STENER-VICTORIN E, et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome[J]. Endocrine Reviews, 2015, 36(5): 487-525. [3] KEEFE C C, GOLDMAN M M, ZHANG K, et al. Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry[J]. PLoS One, 2014, 9(4): e93805. [4] WALTERS K A, BERTOLDO M J, HANDELSMAN D J. Evidence from animal models on the pathogenesis of PCOS[J]. Best Practice & Research Clinical Endocrinology & Metabolism, 2018, 32(3): 271-281. [5] FUJIBE Y, BABA T, NAGAO S, et al. Androgen potentiates the expression of FSH receptor and supports preantral follicle development in mice[J]. Journal of Ovarian Research, 2019, 12(1): 31. [6] TSUCHIYA Y, NAKAJIMA M, YOKOI T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human[J]. Cancer Letters, 2005, 227(2): 115-124. [7] WALTERS K A, HANDELSMAN D J. Role of androgens in the ovary[J]. Molecular and Cellular Endocrinology, 2018, 465: 36-47. [8] YIN M, WANG X, YAO G, et al. Transactivation of micrornA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins[J]. Journal of Biological Chemistry, 2014, 289(26): 18239-18257. [9] LIU Y D, LI Y, FENG S X, et al. Long noncoding RNAs: Potential regulators involved in the pathogenesis of polycystic ovary syndrome[J]. Endocrinology, 2017, 158(11): 3890-3899. [10] CORRIE L, GULATI M, SINGH S K, et al. Recent updates on animal models for understanding the etiopathogenesis of polycystic ovarian syndrome[J]. Life Sciences, 2021, 280: 119753. [11] SINGH P, SRIVASTAVA R K, KRISHNA A. Effects of gonadotropin-releasing hormone agonist and antagonist on ovarian activity in a mouse model for polycystic ovary[J]. The Journal of Steroid Biochemistry and Molecular Biology, 2016, 163: 35-44. [12] BYERS S L, WILES M V, DUNN S L, et al. Mouse estrous cycle identification tool and images[J]. PLoS One, 2012, 7(4): e35538. [13] DI EMIDIO G, REA F, PLACIDI M, et al. Regulatory functions of L-carnitine, acetyl, and propionyl L-carnitine in a PCOS mouse model: Focus on antioxidant/antiglycative molecular pathways in the ovarian microenvironment[J]. Antioxidants, 2020, 9(9): 867. [14] SALIMI-ASL M, MOZDARANI H, KADIVAR M. Up-regulation of miR-21 and 146a expression and increased DNA damage frequency in a mouse model of polycystic ovary syndrome (PCOS)[J]. Bioimpacts, 2016, 6(2): 85-91. [15] JIMENEZ P T, FROLOVA A I, CHI M M, et al. DHEA-mediated inhibition of the pentose phosphate pathway alters oocyte lipid metabolism in mice[J]. Endocrinology, 2013, 154(12): 4835-4844. [16] YU Q, HAO S, WANG H, et al. Depression-like behavior in a dehydroepiandrosterone——Induced mouse model of polycystic ovary syndrome[J]. Biology of Reproduction, 2016, 95(4): 79. [17] BURGER H G. Androgen production in women[J]. Fertility and Sterility, 2002, 77(Suppl 4): S3-S5. [18] SATHYAPALAN T, AL-QAISSI A, KILPATRICK E S, et al. Salivary testosterone measurement in women with and without polycystic ovary syndrome[J]. Scientific Reports, 2017, 7(1): 3589. [19] YUAN C, HUANG W Q, GUO J H, et al. Involvement of kisspeptin in androgen-induced hypothalamic endoplasmic reticulum stress and its rescuing effect in PCOS rats[J]. Biochimica et Biophysica Acta-Molecular Basis of Disease, 2021, 1867(12): 166242. [20] JOHNSTON W F, SALMON M, SU G, et al. Aromatase is required for female abdominal aortic aneurysm protection[J]. Journal of Vascular Surgery, 2015, 61(6): 1565-1574. [21] STOCCO C. Aromatase expression in the ovary: Hormonal and molecular regulation[J]. Steroids, 2008, 73(5): 473-487. [22] DEWAILLY D, ROBIN G, PEIGNE M, et al. Interactions between androgens, FSH, anti-mullerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary[J]. Human Reproduction Update, 2016, 22(6): 709-724. [23] CATTEAU-JONARD S, DEWAILLY D. Pathophysiology of polycystic ovary syndrome: The role of hyperandrogenism[J]. Frontiers of Hormone Research, 2013, 40: 22-27. [24] SALVETTI N R, BARAVALLE C, MIRA G A, et al. Heat shock protein 70 and sex steroid receptors in the follicular structures of induced ovarian cysts[J]. Reproduction in Domestic Animals, 2009, 44(5): 805-814. [25] ORTEGA H H, SALVETTI N R, PADMANABHAN V. Developmental programming: Prenatal androgen excess disrupts ovarian steroid receptor balance[J]. Reproduction, 2009, 137(5): 865-877. [26] PIERRE A, TAIEB J, GITON F, et al. Dysregulation of the anti-mullerian hormone system by steroids in women with polycystic ovary syndrome[J]. Journal of Clinical Endocrinology & Metabolism, 2017, 102(11): 3970-3978. |